Evosep Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 48

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $40M

  • Investors
  • 2

Evosep General Information

Description

Developer of clinical proteomics designed to improve quality of life and patient care. The company is developing new technologies and solutions to make sample separation faster and more robust than today's alternatives for clinical and large-scale proteomics, enabling doctors to radically innovate the performance of protein-based clinical diagnostics, initially through collaborations.

Contact Information

Website
www.evosep.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Corporate Office
  • Buchwaldsgade 35
  • Third Floor, Odense C
  • 5000 Odense
  • Denmark

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Evosep Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 09-Jan-2023 $40M 000.00 Completed Generating Revenue
3. Early Stage VC 31-Dec-2018 00.000 00.000 00.000 Completed Generating Revenue
2. Early Stage VC 31-Dec-2017 $1.27M $3.08M 00.000 Completed Generating Revenue
1. Early Stage VC 30-Jun-2016 $1.81M $1.81M 00.000 Completed Generating Revenue
To view Evosep’s complete valuation and funding history, request access »

Evosep Patents

Evosep Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3519807-A1 System for subjecting a sample to chromatographic analysis Pending 28-Sep-2016 00000000000
US-20190250130-A1 System for subjecting a sample to chromatographic analysis Pending 28-Sep-2016 00000000000 0
EP-3519807-A4 System for subjecting a sample to chromatographic analysis Pending 28-Sep-2016 00000000000 0
US-20200041467-A1 Chromatographic analysis with low pressure dual gradient refocusing Pending 28-Sep-2016 000000000
EP-3519808-A4 Chromatographic analysis with low pressure dual gradient refocusing Active 28-Sep-2016 G01N30/34 0
To view Evosep’s complete patent history, request access »

Evosep Executive Team (6)

Name Title Board Seat Contact Info
Morten Bern Chief Executive Officer
Ole Vorm Founder, Chairman & Director
Jens Christensen VP Finance
Erik Verschuuren Head of Global Sales
Ole Bjeld Hørning Head of Technology
You’re viewing 5 of 6 executive team members. Get the full list »

Evosep Board Members (4)

Name Representing Role Since
Marten Winge Self Board Member 000 0000
Stephen van Helden Novo Holdings Board Member 000 0000
Tonni Bülow-Nielsen Self Board Member 000 0000
You’re viewing 3 of 4 board members. Get the full list »

Evosep Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Evosep Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Novo Holdings Asset Manager Minority 000 0000 000000 0
Denmark's Export and Investment Fund Venture Capital Minority 000 0000 000000 0
To view Evosep’s complete investors history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »